Podocyturia is significantly elevated in untreated vs treated Fabry adult patients
- 557 Downloads
Proteinuria suggests kidney involvement in Fabry disease. We assessed podocyturia, an early biomarker, in controls and patients with and without enzyme therapy, correlating podocyturia with proteinuria and renal function.
Cross-sectional study (n = 67): controls (Group 1, n = 30) vs. Fabry disease (Group 2, n = 37) subdivided into untreated (2A, n = 19) and treated (2B, n = 18). Variables evaluated: age, gender, creatinine, CKD-EPI, proteinuria, podocyte count/10 20× microscopy power fields, podocytes/100 ml urine, podocytes/g creatininuria (results expressed as median and range).
Group 1 vs. 2 did not differ concerning age, gender and CKD-EPI, but differed regarding proteinuria and podocyturia. Group 2A vs. 2B: age: 29 (18–74) vs. 43 (18–65) years (p = ns); gender: males n = 3 (16 %) vs. n = 9 (50 %). Proteinuria was significantly higher in Fabry treated patients, while CKD-EPI and podocyturia were significantly elevated in untreated individuals. Significant correlations: group 2A: age-proteinuria, ρ = 0.62 (p = 0.0044); age-CKD-EPI, ρ = −0.84 (p < 0.0001); podocyturia-podocytes/100 ml urine, ρ = 0.99 (p = 0.0001); podocyturia-podocytes/g creatininuria ρ = 0.86 (p = 0.0003), podocytes/100 ml urine-podocytes/g urinary creatinine, ρ = 0.84 (p = 0.0004); proteinuria-CKD-EPI, ρ = −0.68 (p = 0.0013). Group 2B: podocyturia-podocytes/100 ml urine, ρ = 0.88 (p < 0.0001); podocyturia-podocytes/g creatininuria, ρ = 0.84 (p < 0.0001); podocytes/100 ml urine-podocytes/g creatininuria, ρ = 0.94 (p < 0.0001); CKD-EPI-proteinuria, ρ = -0.66 (p = 0.0028).
Patients with Fabry disease display heavy podocyturia; those untreated present significantly higher podocyturia, lower proteinuria and better renal function than those who are treated, suggesting that therapy may be started at advanced stages. Podocyturia may antedate proteinuria, and enzyme therapy may protect against podocyte loss.
KeywordsFabry disease proteinuria Podocyte Podocyturia Α-galactosidase
We wish to thank Dr Rosanna Coppo for reviewing our manuscript, and Ms. Laura Ares and Ms. Marina Fernandez for their professional assistance.
Compliance with ethical standards
Conflict of interests
Hernán Trimarchi is a consultant to Genzyme for the product alpha galactosidase-β.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.Desnick RJ, Ioannou Y, Eng CM (2001) α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3733–3774Google Scholar
- 4.Trimarchi H, Forrester M, Lombi F et al (2014) Amiloride as an alternate adjuvant antiproteinuric agent in Fabry disease. The potential roles of plasmin and uPAR. Case Reports in Nephrology 1–6: ID 854521Google Scholar
- 12.Trimarchi H, Canzonieri R, Muryan A, et al (2015) Copious podocyturia without proteinuria and with normal renal function in a young adult with Fabry disease. Case Reports in Nephrology 257628Google Scholar
- 18.Smoyer WE, Mundel P, Gupta E et al (1997) Podocyte alpha-actinin induction precedes foot process effacement in experimental nephrotic syndrome. Am J Physiol 273 Renal Physiol 42:F150–F157Google Scholar
- 22.Trimarchi H (2015) Podocyturia. What is in a name? J Translat Internal Med 3:51–56Google Scholar
- 23.Jim B, Jean-Louis P, Qipo A et al (2012) Podocyturia as a diagnostic marker of preeclampsia amongst high-risk pregnant patients. J of Pregnancy ID 984630. doi: 10.1155/2012/984630
- 30.Trimarchi H (2015) Plasmin, urokinase plasminogen activator receptor and amiloride in the nephrotic syndrome. In: Nephrotic syndrome. Etiology, pathogenesis and pathology. Mubarak M (ed) Nova Biomedical, New YorkGoogle Scholar